Hiv infection and intravenous drug use: Critical issues in transmission dynamics, infection outcomes, and prevention

Don Des Jarlais, Samuel R. Friedman, Rand L. Stoneburner

Research output: Contribution to journalArticle

Abstract

As the second largest group of persons to have been infected with human immunodeficiency virus (HIV), and the most likely to transmit HIV to heterosexual partners in the United States and Europe, iv drug users will play an increasingly important role in the future of the AIDS epidemic. This paper reviews five emerging critical issues regarding HIV infection among iv drug users. In epidemiology, rates of drug injection and anonymous sharing of injection equipment appear related to rapid spread of HIV among iv drug users, while heterosexual transmission from iv drug users appears to have been occurring at a relatively slow but constant rate. Data exist that support a gender-related cofactor and a continuing drug injection cofactor, but mechanisms for these potential cofactors have not been determined. Besides frank AIDS, HIV infection also appears to lead to epidemic-level increases in a variety of fatal infections among iv drug users. Several studies of prevention show active risk reduction among iv drug users, but new methods are urgently needed to increase amount of risk reduction.

Original languageEnglish (US)
Pages (from-to)151-158
Number of pages8
JournalReviews of Infectious Diseases
Volume10
Issue number1
DOIs
StatePublished - Jan 1 1988

Fingerprint

Infectious Disease Transmission
Drug Users
HIV
Infection
Pharmaceutical Preparations
Heterosexuality
Virus Diseases
Risk Reduction Behavior
Injections
Acquired Immunodeficiency Syndrome
Epidemiology
Equipment and Supplies

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Hiv infection and intravenous drug use : Critical issues in transmission dynamics, infection outcomes, and prevention. / Des Jarlais, Don; Friedman, Samuel R.; Stoneburner, Rand L.

In: Reviews of Infectious Diseases, Vol. 10, No. 1, 01.01.1988, p. 151-158.

Research output: Contribution to journalArticle

@article{204b9390808943e5a301784d7e33ef0d,
title = "Hiv infection and intravenous drug use: Critical issues in transmission dynamics, infection outcomes, and prevention",
abstract = "As the second largest group of persons to have been infected with human immunodeficiency virus (HIV), and the most likely to transmit HIV to heterosexual partners in the United States and Europe, iv drug users will play an increasingly important role in the future of the AIDS epidemic. This paper reviews five emerging critical issues regarding HIV infection among iv drug users. In epidemiology, rates of drug injection and anonymous sharing of injection equipment appear related to rapid spread of HIV among iv drug users, while heterosexual transmission from iv drug users appears to have been occurring at a relatively slow but constant rate. Data exist that support a gender-related cofactor and a continuing drug injection cofactor, but mechanisms for these potential cofactors have not been determined. Besides frank AIDS, HIV infection also appears to lead to epidemic-level increases in a variety of fatal infections among iv drug users. Several studies of prevention show active risk reduction among iv drug users, but new methods are urgently needed to increase amount of risk reduction.",
author = "{Des Jarlais}, Don and Friedman, {Samuel R.} and Stoneburner, {Rand L.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1093/clinids/10.1.151",
language = "English (US)",
volume = "10",
pages = "151--158",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Hiv infection and intravenous drug use

T2 - Critical issues in transmission dynamics, infection outcomes, and prevention

AU - Des Jarlais, Don

AU - Friedman, Samuel R.

AU - Stoneburner, Rand L.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - As the second largest group of persons to have been infected with human immunodeficiency virus (HIV), and the most likely to transmit HIV to heterosexual partners in the United States and Europe, iv drug users will play an increasingly important role in the future of the AIDS epidemic. This paper reviews five emerging critical issues regarding HIV infection among iv drug users. In epidemiology, rates of drug injection and anonymous sharing of injection equipment appear related to rapid spread of HIV among iv drug users, while heterosexual transmission from iv drug users appears to have been occurring at a relatively slow but constant rate. Data exist that support a gender-related cofactor and a continuing drug injection cofactor, but mechanisms for these potential cofactors have not been determined. Besides frank AIDS, HIV infection also appears to lead to epidemic-level increases in a variety of fatal infections among iv drug users. Several studies of prevention show active risk reduction among iv drug users, but new methods are urgently needed to increase amount of risk reduction.

AB - As the second largest group of persons to have been infected with human immunodeficiency virus (HIV), and the most likely to transmit HIV to heterosexual partners in the United States and Europe, iv drug users will play an increasingly important role in the future of the AIDS epidemic. This paper reviews five emerging critical issues regarding HIV infection among iv drug users. In epidemiology, rates of drug injection and anonymous sharing of injection equipment appear related to rapid spread of HIV among iv drug users, while heterosexual transmission from iv drug users appears to have been occurring at a relatively slow but constant rate. Data exist that support a gender-related cofactor and a continuing drug injection cofactor, but mechanisms for these potential cofactors have not been determined. Besides frank AIDS, HIV infection also appears to lead to epidemic-level increases in a variety of fatal infections among iv drug users. Several studies of prevention show active risk reduction among iv drug users, but new methods are urgently needed to increase amount of risk reduction.

UR - http://www.scopus.com/inward/record.url?scp=0023674637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023674637&partnerID=8YFLogxK

U2 - 10.1093/clinids/10.1.151

DO - 10.1093/clinids/10.1.151

M3 - Article

C2 - 3281219

AN - SCOPUS:0023674637

VL - 10

SP - 151

EP - 158

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 1

ER -